Datapoint: Apellis Pharmaceuticals to Take on Alexion in PNH

The FDA on May 14 approved Apellis Pharmaceuticals’ Empaveli as a first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare and deadly chronic blood disorder. The biotech said it will initially target patients that have not responded to Soliris and/or Ultomiris, both C5 inhibitors from Alexion Pharmaceuticals. Under the pharmacy benefit, Soliris holds covered or better status for 53% of all covered lives. It is not covered for 26.3% of all lives.

SOURCE: MMIT Analytics, as of 5/19/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today